nach oben

Erschienen in:

12.08.2020 | Urogenital

T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy

verfasst von: Chongpeng Sun, Shiyang Wang, Aritrick Chatterjee, Milica Medved, Scott Eggener, Gregory S. Karczmar, Aytekin Oto

Erschienen in: European Radiology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate utility of T2*-weighted (T2*W) MRI as a tool for intra-operative identification of ablation zone extent during focal laser ablation (FLA) of prostate cancer (PCa), as compared to the current standard of contrast-enhanced T1-weighted (T1W) MRI.

Methods

Fourteen patients with biopsy-confirmed low- to intermediate-risk localized PCa received MRI-guided (1.5 T) FLA thermotherapy. Following FLA, axial multiple-TE T2*W images, diffusion-weighted images (DWI), and T2-weighted (T2W) images were acquired. Pre- and post-contrast T1W images were also acquired to assess ablation zone (n = 14) extent, as reference standard. Apparent diffusion coefficient (ADC) maps and subtracted contrast-enhanced T1W (sceT1W) images were calculated. Ablation zone regions of interest (ROIs) were outlined manually on all ablated slices. The contrast-to-noise ratio (CBR) of the ablation site ROI relative to the untreated contralateral prostate tissue was calculated on T2*W images and ADC maps and compared to that in sceT1W images.

Results

CBRs in ablation ROIs on T2*W images (TE = 32, 63 ms) did not differ (p = 0.33, 0.25) from those in sceT1W images. Bland–Altman plots of ROI size and CBR in ablation sites showed good agreement between T2*W (TE = 32, 63 ms) and sceT1W images, with ROI sizes on T2*W (TE = 63 ms) strongly correlated (r = 0.64, p = 0.013) and within 15% of those in sceT1W images.

Conclusions

In detected ablation zone ROI size and CBR, non-contrast-enhanced T2*W MRI is comparable to contrast-enhanced T1W MRI, presenting as a potential method for intra-procedural monitoring of FLA for PCa.

Key Points

• T2*-weighted MR images with long TE visualize post-procedure focal laser ablation zone comparably to the contrast-enhanced T1-weighted MRI.

• T2*-weighted MRI could be used as a plausible method for repeated intra-operative monitoring of thermal ablation zone in prostate cancer, avoiding potential toxicity due to heating of contrast agent.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRef

Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172:1297–1301CrossRef

American Cancer Society (2018) Cancer facts & figures 2018. American Cancer Society, Atlanta. Available via: http://www.cancer.org/research/cancer-facts-statistics.html. Accessed 12 April 2018

Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V (2008) Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68:1380–1386CrossRef

Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242CrossRef

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448CrossRef

Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261CrossRef

Weerakoon M, Papa N, Lawrentschuk N et al (2015) The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int 115(Suppl 5):50–56CrossRef

Lindner U, Lawrentschuk N, Trachtenberg J (2010) Focal laser ablation for localized prostate cancer. J Endourol 24:791–797CrossRef

10.

Oto A, Sethi I, Karczmar G et al (2013) MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 267:932–940CrossRef

11.

Eggener SE, Yousuf A, Watson S, Wang S, Oto A (2016) Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol 196:1670–1675CrossRef

12.

Lepor H, Llukani E, Sperling D, Futterer JJ (2015) Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur Urol 68:924–926CrossRef

13.

Natarajan S, Raman S, Priester AM et al (2016) Focal laser ablation of prostate cancer: phase I clinical trial. J Urol 196:68–75CrossRef

14.

Raz O, Haider MA, Davidson SR et al (2010) Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 58:173–177CrossRef

15.

Westin C, Chatterjee A, Ku E et al (2018) MRI findings after MRI-guided focal laser ablation of prostate cancer. AJR Am J Roentgenol 211:595–604CrossRef

16.

Lenard ZM, McDannold NJ, Fennessy FM et al (2008) Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--imaging predictors of success. Radiology. 249:187–194CrossRef

17.

Mumtaz H, Hall-Craggs MA, Wotherspoon A et al (1996) Laser therapy for breast cancer: MR imaging and histopathologic correlation. Radiology. 200:651–658CrossRef

18.

Patel NV, Jethwa PR, Barrese JC, Hargreaves EL, Danish SF (2013) Volumetric trends associated with MRI-guided laser-induced thermal therapy (LITT) for intracranial tumors. Lasers Surg Med 45:362–369CrossRef

19.

Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M (2007) Prostate tissue analysis immediately following magnetic resonance imaging guided transurethral ultrasound thermal therapy. J Urol 178:1080–1085CrossRef

20.

Woodrum DA, Kawashima A, Gorny KR, Mynderse LA (2017) Prostate cancer: state of the art imaging and focal treatment. Clin Radiol 72:665–679CrossRef

21.

Bomers JGR, Cornel EB, Futterer JJ et al (2017) MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. World J Urol 35:703–711CrossRef

22.

Toupin S, Bour P, Lepetit-Coiffé M et al (2017) Feasibility of real-time MR thermal dose mapping for predicting radiofrequency ablation outcome in the myocardium in vivo. J Cardiovasc Magn Reson 19:14CrossRef

23.

Partanen A, Yerram NK, Trivedi H et al (2013) Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. BJU Int 112:508–516CrossRef

24.

Staruch RM, Nofiele J, Walker J et al (2017) Assessment of acute thermal damage volumes in muscle using magnetization-prepared 3D T2 -weighted imaging following MRI-guided high-intensity focused ultrasound therapy. J Magn Reson Imaging 46:354–364CrossRef

25.

Lam MK, de Greef M, Bouwman JG, Moonen CT, Viergever MA, Bartels LW (2015) Multi-gradient echo MR thermometry for monitoring of the near-field area during MR-guided high intensity focused ultrasound heating. Phys Med Biol 60:7729–7745CrossRef

26.

Wang S, Fan X, Yousuf A, Eggener SE, Karczmar G, Oto A (2019) Evaluation of focal laser ablation of prostate cancer using high spectral and spatial resolution imaging: a pilot study. J Magn Reson Imaging 49:1374–1380CrossRef

27.

Wenger H, Yousuf A, Oto A, Eggener S (2014) Laser ablation as focal therapy for prostate cancer. Curr Opin Urol 24:236–240CrossRef

28.

De Poorter J (1995) Noninvasive MRI thermometry with the proton resonance frequency method: study of susceptibility effects. Magn Reson Med 34:359–367CrossRef

29.

Quesson B, de Zwart JA, Moonen CT (2000) Magnetic resonance temperature imaging for guidance of thermotherapy. J Magn Reson Imaging 12:525–533CrossRef

30.

Dromain C, de Baere T, Elias D et al (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255–262CrossRef

31.

Yoneyama M, Takahara T, Kwee TC, Nakamura M, Tabuchi T (2013) Rapid high resolution MR neurography with a diffusion-weighted pre-pulse. Magn Reson Med Sci 12:111–119CrossRef

32.

Chen J, Daniel BL, Diederich CJ et al (2008) Monitoring prostate thermal therapy with diffusion-weighted MRI. Magn Reson Med 59:1365–1372CrossRef

33.

Ikink ME, Voogt MJ, van den Bosch MA et al (2014) Diffusion-weighted magnetic resonance imaging using different b-value combinations for the evaluation of treatment results after volumetric MR-guided high-intensity focused ultrasound ablation of uterine fibroids. Eur Radiol 24:2118–2127CrossRef

34.

Lindner U, Lawrentschuk N, Weersink RA et al (2010) Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 57:1111–1114CrossRef

Titel: T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy
verfasst von: Chongpeng Sun
Shiyang Wang
Aritrick Chatterjee
Milica Medved
Scott Eggener
Gregory S. Karczmar
Aytekin Oto
Publikationsdatum: 12.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 1/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-07127-7

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging

Diffusion-weighted MR volume and apparent diffusion coefficient for discriminating lymph node metastases and good response after chemoradiation therapy in locally advanced rectal cancer

The implications of missed or misinterpreted cases of pancreatic ductal adenocarcinoma on imaging: a multi-centered population-based study

Automated quantification of COVID-19 severity and progression using chest CT images

Imaging, biopsy and non-surgical treatment of thyroid lesions: where are we at?

Liver MRI with amide proton transfer imaging: feasibility and accuracy for the characterization of focal liver lesions

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie